Replimune Group (NASDAQ:REPL) Given New $20.00 Price Target at JPMorgan Chase & Co.

Posted by Francis Steltz on Aug 7th, 2026

Replimune Group (NASDAQ:REPL – Get Free Report) had its price target lifted by JPMorgan Chase & Co. from $17.00 to $20.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 64.22% from the company’s current price.

Several other analysts have also commented on the company. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $12.00 to $19.00 in a report on Friday. HC Wainwright reissued a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. BMO Capital Markets raised Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a report on Tuesday, June 30th. Finally, Piper Sandler upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Replimune Group has an average rating of “Moderate Buy” and a consensus price target of $12.86.

Get Our Latest Stock Analysis on REPL

Replimune Group Stock Down 5.3%

REPL stock traded down $0.68 during trading on Friday, reaching $12.18. 5,571,197 shares of the company traded hands, compared to its average volume of 4,978,161. The business has a 50 day simple moving average of $10.08 and a 200 day simple moving average of $7.51. Replimune Group has a 12 month low of $1.50 and a 12 month high of $13.90. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -3.64 and a beta of 0.88.

Replimune Group (NASDAQ:REPL – Get Free Report) last released its quarterly earnings results on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). On average, equities research analysts anticipate that Replimune Group will post -2.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the sale, the insider directly owned 180,962 shares in the company, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. EcoR1 Capital LLC acquired a new position in shares of Replimune Group during the 1st quarter valued at about $7,650,000. Seven Fleet Capital Management LP purchased a new position in Replimune Group during the first quarter worth about $921,000. Jefferies Financial Group Inc. acquired a new position in Replimune Group in the 4th quarter valued at about $6,942,000. Candriam S.C.A. acquired a new position in Replimune Group in the 1st quarter valued at about $3,014,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Replimune Group in the 4th quarter valued at approximately $598,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

More Replimune Group News

Here are the key news stories impacting Replimune Group this week:

Positive Sentiment: The FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1 regimen. The approval gives Replimune its first marketed product after two prior regulatory rejections and could create a revenue base for the biotechnology company. Reuters FDA approval article
Positive Sentiment: Investors purchased 25,580 REPL call options, roughly 98% above average daily call volume. The activity may indicate increased bullish speculation or hedging around the FDA decision and the company’s commercial launch, although options volume alone does not establish a sustained investment trend.
Neutral Sentiment: Coverage emphasized that approval came after earlier rejections tied to clinical-data quality and study-design concerns. Those issues remain important for investors monitoring post-approval requirements, confirmatory trials and the broader commercial rollout. Wall Street Journal FDA approval article
Negative Sentiment: A securities class action was filed in Massachusetts covering investors who acquired Replimune securities from October 20, 2025, through April 10, 2026. The complaint alleges that the company made misleading statements or failed to disclose concerns about its BLA, including reliance on an early analysis of only 40 patients and deficiencies that could have led to FDA rejection. The allegations have not been proven. Gainey McKenna class action announcement
Negative Sentiment: Several additional law firms, including Robbins, Pomerantz and Bragar Eagel & Squire, announced investigations or investor solicitations concerning alleged misrepresentations about RP1’s efficacy and viability. The mounting legal attention adds reputational, financial and headline risk. Robbins LLP investor alert

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.